For patients hospitalized for acute heart failure, treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin produces clinical benefit, according to a study published online April 4 in Circulation to coincide with the annual meeting of the American College of Cardiology, held from April 2 to 4 in Washington, D.C.

Mikhail N. Kosiborod, MD, from Saint Luke's Mid America Heart Institute in Kansas City, Missouri, and colleagues conducted a secondary analysis to examine the impact of the SGLT2 inhibitor empagliflozin on symptoms, physical limitations, and quality of life among patients hospitalized for acute heart failure. 

"Our results are of clinical importance, because very few therapies have been previously shown to improve symptoms and functional status in the early postdischarge period in individuals hospitalized with acute heart failure," the authors write.

Read the full HealthDay article: Empagliflozin Offers Clinical Benefit in Heart Failure

Read more >

Related Content

  • Person, Hair, Nurse, Face, Female, Word
    Nicole's story

    "What we do is so vital. We have so much power as nurses." Nicole Roberson, Registered Nurse, Neuroscience ICU, Saint Luke's Hospital of Kansas City

    Read more >
  • Person, Doctor, Clothing, Apparel, Lab Coat, Coat, Face, Nurse
    Deb's story

    Deb Day, Registered Nurse · Anderson County Hospital "I am a Saint Luke's Nurse.  Nurses are the lifeblood of Saint Luke’s compassionate care, and the life-changing work they do is...

    Read more >
  • Apparel, Clothing, Coat, Lab Coat, Person, Doctor
    Danielle's story

    "You get those rare moments that you're reminded why you went into this field, and it makes everything so much better." Danielle Hammontree, Certified Family Nurse Practitioner, Saint Luke’s East Hospital

    Read more >